Both EGFR-mutant and ALK-rearranged lung cancers utilise common mechanisms of resistance, including the development of secondary mutations in the tyrosine kinase domain, driver gene amplification, phenotypic alterations, and reactivation of the primary signalling pathways through alternative signalling molecules [27–29]. This evidence concerns the gene EGFR and lung cancer.